Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2923122 | 1.00 | TSHR (0.40) | TSHRTHRBLMNAMEN1KMT2A | |
| SCHEMBL2923009 | 1.00 | TSHR (0.40) | TSHRTHRBLMNAMEN1KMT2A | |
| SCHEMBL2922066 | 1.00 | TSHR (0.40) | TSHRTHRBLMNAMEN1KMT2A | |
| SCHEMBL2017168 | 1.00 | TSHR (0.40) | TSHRTHRBLMNAMEN1KMT2A | |
| SCHEMBL2919557 | 1.00 | TSHR (0.40) | TSHRTHRBLMNAMEN1KMT2A | |
| SCHEMBL2024917 | 1.00 | TSHR (0.40) | TSHRTHRBLMNAMEN1KMT2A | |
| SCHEMBL2020825 | 1.00 | TSHR (0.40) | TSHRTHRBLMNAMEN1KMT2A | |
| SCHEMBL2917558 | 1.00 | TSHR (0.40) | TSHRTHRBLMNAMEN1KMT2A | |
| SCHEMBL2017120 | 1.00 | TSHR (0.40) | TSHRTHRBLMNAMEN1KMT2A | |
| SCHEMBL2912529 | 1.00 | TSHR (0.40) | TSHRTHRBLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2341108-B1 | Surface treatment method for solid material | SHINETSU CHEMICAL CO (JP) | 2014-07-02 | — | — | EP | disclosed |
| US-8541631-B2 | Surface treatment method for solid material | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| EP-2341108-A1 | Surface treatment method for solid material | Shin-Etsu Chemical Co., Ltd. (JP) | 2011-07-06 | — | — | EP | disclosed |
| US-20110160464-A1 | SURFACE TREATMENT METHOD FOR SOLID MATERIAL | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-1688423-B1 | Silylation of hydroxyl group-containing compounds | SHINETSU CHEMICAL CO (JP) | 2010-09-08 | — | — | EP | disclosed |
| EP-1688423-A1 | Silylation of hydroxyl group-containing compounds | Shin-Etsu Chemical Co., Ltd. (JP) | 2006-08-09 | — | — | EP | disclosed |
| EP-1334975-B1 | Silylation of hydroxyl group-containing compounds | SHINETSU CHEMICAL CO (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-6875880-B2 | Silylation of hydroxyl groups | SHIN-ETSU CHEMICAL, CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| EP-1334975-A1 | Silylation of hydroxyl group-containing compounds | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-20030139619-A1 | Silylation of hydroxyl groups | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160464-A1 | SURFACE TREATMENT METHOD FOR SOLID MATERIAL | H1-2, H1-0, HRH3 | TSHR 814/4885THRB 1783/4885LMNA 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.